Program
obefazimod
Also written as “ABX464”, “ABX464 50mg” and “Obefazimod 50 mg Capsule”.
Its studies are mostly in Colitis, Ulcerative · Crohn Disease · Arthritis, Rheumatoid · HIV Infections · COVID-19, led by Abivax.
Drug pageABX464: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abivax | 214 open or running | phase 3since Apr 3, 2019 | Apr 10, 2015 | Dec 2026phase 2 · NCT06456593 |
Also a collaborator on its studies: Quotient Sciences and Orion Corporation, Orion Pharma.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Apr 10, 2015.
- Nov 29, 2018Phase 2 study in Colitis, UlcerativeNCT03760003 · 355 enrolled · United States, Austria, Belarus and more
- Jan 15, 2019Phase 2 study in Arthritis, RheumatoidNCT03813199 · 60 enrolled · Belgium, Czechia, France and more
- Apr 3, 2019Phase 3 study in Crohn DiseaseNCT03905109 · Belgium
- Jul 5, 2019Phase 2 study in Colitis, UlcerativeNCT04023396 · 217 enrolled · Austria, Belarus, Belgium and more
- Aug 6, 2019Phase 2 study in Arthritis, RheumatoidNCT04049448 · 40 enrolled · Belgium, France, Hungary and more
- May 18, 2020Phase 3 study in COVID-19NCT04393038 · 509 enrolled · Belgium, Brazil, France and more
- Jul 28, 2021Named obefazimodINNProposed as its International Nonproprietary Name in WHO's List 125 · before, ABX464
- Aug 30, 2021Phase 1 study in Healthy VolunteersNCT05032560 · 48 enrolled · Japan
- Oct 11, 2021Phase 1 study in HealthyNCT05121714 · 59 enrolled · United Kingdom
- Dec 15, 2021Phase 2 study in Colitis, UlcerativeNCT05177835 · 203 enrolled · Austria, Belgium, Canada and more
- Aug 17, 20222 phase 3 studies in Colitis, UlcerativeNCT05507216, NCT05507203
- Sep 7, 2022Phase 3 study in Colitis, UlcerativeNCT05535946 · 1,116 enrolled · United States, Argentina, Australia and more
- May 16, 2024Phase 2 study in Crohn DiseaseNCT06456593 · 212 planned · United States, Belgium, Czechia and more
- Feb 25, 2026Phase 1 study in HealthyNCT07453784 · 44 planned · United Kingdom
- Nov 13, 2026Primary completion moved from 2026-09 to 2027-04Date moved laterphase 1 · +7 months · NCT07453784
Ahead
- Dec 2026Primary completion: phase 2 study in Crohn DiseaseNCT06456593
- Apr 2027Primary completion: phase 1 study in HealthyNCT07453784
- Mar 2028Primary completion: phase 2 study in Colitis, UlcerativeNCT05177835
TargetBeta
“Cap binding complex modulator”ChEMBL 37, by rule
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07453784Healthy · United Kingdom | 1 | Recruiting | Apr 2027 | 44 |
| NCT06456593Crohn Disease · United States, Belgium, Czechia and more | 2 | Recruiting | Dec 2026 | 212 |
| NCT05535946Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 28, 2026 | 1,116 |
| NCT05507216Colitis, Ulcerative · United States, Argentina, Belgium and more | 3 | Completed | Jun 24, 2025 | 636 |
| NCT05507203Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Jun 24, 2025 | 639 |
| NCT05177835Colitis, Ulcerative · Austria, Belgium, Canada and more | 2 | Active, not recruiting | Mar 2028 | 203 |
| NCT05121714Healthy · United Kingdom | 1 | Completed | May 18, 2021 | 59 |
| NCT05032560Healthy Volunteers · Japan | 1 | Completed | Feb 18, 2022 | 48 |
| NCT04393038COVID-19 · Belgium, Brazil, France and more | 3 | Terminated | Mar 5, 2021 | 509 |
| NCT04049448Arthritis, Rheumatoid · Belgium, France, Hungary and more | 2 | Completed | Jan 23, 2023 | 40 |
| NCT04023396Colitis, Ulcerative · Austria, Belarus, Belgium and more | 2 | Completed | Feb 23, 2023 | 217 |
| NCT03905109Crohn Disease · Belgium | 3 | Withdrawn | Sep 19, 2022 | 0 |
| NCT03813199Arthritis, Rheumatoid · Belgium, Czechia, France and more | 2 | Completed | Apr 27, 2021 | 60 |
| NCT03760003Colitis, Ulcerative · United States, Austria, Belarus and more | 2 | Completed | Apr 1, 2021 | 355 |
| NCT03368118Colitis, Ulcerative · Belgium | 2 | Completed | Jul 12, 2022 | 22 |
| NCT03093259Colitis, Ulcerative · Austria, Belgium, Czechia and more | 2 | Completed | Jul 25, 2018 | 32 |
| NCT02990325HIV Infections · Spain | 2 | Completed | Dec 27, 2018 | 36 |
| NCT02792686Healthy Volunteers · France | 1 | Completed | Jul 2014 | 24 |
| NCT02735863HIV Infections · Belgium, France, Spain | 2 | Completed | Aug 30, 2017 | 30 |
| NCT02731885Healthy Volunteers · Mauritius | 1 | Completed | Jun 2015 | 48 |
| NCT02452242Human Immunodeficiency Virus Infections · Mauritius, Thailand | 2 | Completed | Dec 2015 | 70 |
How it is read
Names in the registry
- “ABX464”, 15 entries
- “ABX464 50mg”, 3 entries
- “Obefazimod 50 mg Capsule”, 1 entry
- “Obefazimod”, 1 entry
- “ABX464 100 mg”, 1 entry
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 8 studies
- Crohn Disease, 2 studies
- Arthritis, Rheumatoid, 2 studies
- HIV Infections, 2 studies
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.